Literature DB >> 24588677

Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging.

Mi Hye Yu1, Jung Hoon Kim, Jeong-Hee Yoon, Hyo-Cheol Kim, Jin Wook Chung, Joon Koo Han, Byung-Ihn Choi.   

Abstract

PURPOSE: To assess diagnostic performance and imaging features of gadoxetic acid-enhanced magnetic resonance (MR) imaging in small (≤1-cm) hepatocellular carcinoma (HCC) detection in patients with chronic liver disease.
MATERIALS AND METHODS: The institutional review board approved this retrospective study and waived informed consent. Sixty patients (56 men, four women; mean age, 60.1 years) with HCC (146 lesions; 70 > 1 cm, 76 ≤ 1 cm) underwent gadoxetic acid-enhanced MR imaging. HCC was confirmed at surgical resection (72 lesions; 30 > 1 cm, 42 ≤ 1 cm) or by showing interval growth with typical enhancement patterns at follow-up dynamic computed tomography or MR imaging (74 lesions; 40 > 1 cm, 34 ≤ 1 cm). Two radiologists assessed MR imaging features and graded likelihood of HCC with a five-point confidence scale. Jackknife alternative free-response receiver operating characteristic (JAFROC) method was used.
RESULTS: Mean JAFROC figure of merit for small HCC was 0.717; that for large (>1-cm) HCC was 0.973 with substantial agreement (κ = 0.676). Mean sensitivity and positive predictive value (PPV) were 46.0% (70 of 152) and 48.3% (70 of 145) for small HCC versus 95.0% (133 of 140) and 78.2% (133 of 170) for large HCC, respectively. Eleven of 76 small HCCs (14%) were not seen on MR images, even after careful investigation. MR imaging features of small HCC included arterial enhancement (79%, 60 of 76), hypointensity on hepatobiliary phase (HBP) images (68%, 52 of 76), washout on 3-minute delayed phase images (50%, 38 of 76), hyperintensity on T2-weighted images (43%, 33 of 76), hypointensity on T1-weighted images (32%, 24 of 76), and restriction on diffusion-weighted images (28%, 20 of 72). Arterial enhancement and washout on 3-minute delayed phase images or hypointensity on HBP images occurred in 66% of small HCCs (50 of 76).
CONCLUSION: Diagnostic performance of gadoxetic acid-enhanced MR imaging for small HCC detection is still low, with mean sensitivity of 46.0% (70 of 152) and mean PPV of 48.3% (70 of 145). By adding hypointensity on HBP images as washout, diagnostic performance for small HCC detection can be improved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24588677     DOI: 10.1148/radiol.14131996

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  33 in total

1.  Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19 mm) HCC on extracellular contrast-enhanced MRI.

Authors:  Jingbiao Chen; Sichi Kuang; Yao Zhang; Wenjie Tang; Sidong Xie; Linqi Zhang; Dailin Rong; Bingjun He; Ying Deng; Yuanqiang Xiao; Wenqi Shi; Kathryn Fowler; Jin Wang; Claude B Sirlin
Journal:  Abdom Radiol (NY)       Date:  2020-10-11

Review 2.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

3.  LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI.

Authors:  Ji Soo Song; Eun Jung Choi; Seung Bae Hwang; Hong Pil Hwang; HyeMi Choi
Journal:  Eur Radiol       Date:  2018-06-19       Impact factor: 5.315

Review 4.  Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI.

Authors:  Ijin Joo; Jeong Min Lee
Journal:  Liver Cancer       Date:  2015-12-18       Impact factor: 11.740

5.  Differentiating malignant from benign hyperintense nodules on unenhanced T1-weighted images in patients with chronic liver disease: using gadoxetic acid-enhanced and diffusion-weighted MR imaging.

Authors:  Ji Yoon Moon; Seong Hyun Kim; Seo-Youn Choi; Jeong Ah Hwang; Ji Eun Lee; Jisun Lee
Journal:  Jpn J Radiol       Date:  2018-06-06       Impact factor: 2.374

Review 6.  Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up.

Authors:  Stefano Colagrande; Francesco Regini; Gian Giacomo Taliani; Cosimo Nardi; Andrea Lorenzo Inghilesi
Journal:  World J Hepatol       Date:  2015-05-18

Review 7.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

8.  Study on the diagnosis of small hepatocellular carcinoma caused by hepatitis B cirrhosis via multi-slice spiral CT and MRI.

Authors:  Mei Wang; Congxin Wei; Zhaojuan Shi; Jianzhong Zhu
Journal:  Oncol Lett       Date:  2017-10-31       Impact factor: 2.967

9.  Comparison of hepatocellular carcinoma conspicuity on hepatobiliary phase images with gadoxetate disodium vs. delayed phase images with extracellular cellular contrast agent.

Authors:  So Yeon Kim; En-Haw Wu; Seong Ho Park; Z Jane Wang; Thomas A Hope; Judy Yee; Li-Qin Zhao; Wei-Chou Chang; Benjamin M Yeh
Journal:  Abdom Radiol (NY)       Date:  2016-08

10.  Novel Imaging Diagnosis for Hepatocellular Carcinoma: Consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014).

Authors:  Bang-Bin Chen; Takamichi Murakami; Tiffany Ting-Fang Shih; Michiie Sakamoto; Osamu Matsui; Byung-Ihn Choi; Myeong-Jin Kim; Jeong Min Lee; Ren-Jie Yang; Meng-Su Zeng; Ran-Chou Chen; Ja-Der Liang
Journal:  Liver Cancer       Date:  2015-10-15       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.